Evidence map›Paper›PMID 35802157›Full record

ArticleApplied microbiology and biotechnology2022

A host-vector toolbox for improved secretory protein overproduction in Bacillus subtilis.

Anna Krüger, Norma Welsch, Alexandra Dürwald, Henrike Brundiek, Rainer Wardenga, Henning Piascheck, Hendrik G Mengers, Jana Krabbe, Sandra Beyer, Johannes F Kabisch and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Refined control of CRISPR-Cas9 gene editing inFrontiers in immunology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Anna Krüger *Institute of Technical Microbiology, Hamburg University of Technology, Kasernenstr. 12, 21073, Hamburg, Germany.
Norma Welsch *Pharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany.
Alexandra DürwaldPharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany.
Henrike BrundiekEnzymicals AG, Walther-Rathenau-Straße 49a, 17489, Greifswald, Germany.
Rainer WardengaEnzymicals AG, Walther-Rathenau-Straße 49a, 17489, Greifswald, Germany.
Henning PiascheckInstitute of Technical Microbiology, Hamburg University of Technology, Kasernenstr. 12, 21073, Hamburg, Germany.
Hendrik G MengersInstitute of Applied Microbiology - iAMB, Aachen Biology and Biotechnology - ABBt, RWTH Aachen University, Worringerweg 1, 52074, Aachen, Germany.
Jana KrabbePharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany.
Sandra BeyerPharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany.
Johannes F KabischPharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany.
Lutz PopperStern Enzym GmbH & Co. KG, Kurt-Fischer-Str. 55, 22926, Ahrensburg, Germany.
Tanno HübelMiltenyi Biotec GmbH, Robert-Koch-Str. 1, 17166, Teterow, Germany.
Garabed AntranikianInstitute of Technical Microbiology, Hamburg University of Technology, Kasernenstr. 12, 21073, Hamburg, Germany.
Thomas SchwederPharmaceutical Biotechnology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Str. 3, 17487, Greifswald, Germany. schweder@uni-greifswald.de.ORCID http://orcid.org/0000-0002-7213-3596
Universität Greifswald · DEUniversität Hamburg · DEFischer (Germany) · DEMiltenyi Biotec (Germany) · DENorwegian University of Science and Technology · NORWTH Aachen University · DEUniversitätsmedizin Greifswald · DE

Funding

BMBF 0315400A/BMinistry of Economy, Labour and Tourism of Mecklenburg Vorpommern V-630-F-177-2013/212Ministry of Economy, Labour and Tourism of Mecklenburg Vorpommern V-630-S-177-2013/213
6 · The paper itself

Abstract

Target proteins in biotechnological applications are highly diverse. Therefore, versatile flexible expression systems for their functional overproduction are required. In order to find the right heterologous gene expression strategy, suitable host-vector systems, which combine different genetic circuits, are useful. In this study, we designed a novel Bacillus subtilis expression toolbox, which allows the overproduction and secretion of potentially toxic enzymes. This toolbox comprises a set of 60 expression vectors, which combine two promoter variants, four strong secretion signals, a translation-enhancing downstream box, and three plasmid backbones. This B. subtilis toolbox is based on a tailor-made, clean deletion mutant strain, which is protease and sporulation deficient and exhibits reduced autolysis and secondary metabolism. The appropriateness of this alternative expression platform was tested for the overproduction of two difficult-to-produce eukaryotic model proteins. These included the sulfhydryl oxidase Sox from Saccharomyces cerevisiae, which forms reactive hydrogen peroxide and undesired cross-linking of functional proteins, and the human interleukin-1β, a pro-inflammatory cytokine. For the best performing Sox and interleukin, overproducing and secreting variants of these new B. subtilis toolbox fermentation strategies were developed and tested. This study demonstrates the suitability of the prokaryotic B. subtilis host-vector system for the extracellular production of two eukaryotic proteins with biotechnological relevance. KEY POINTS: • Construction of a versatile Bacillus subtilis gene expression toolbox. • Verification of the toolbox by the secretory overproduction of two difficult-to-express proteins. • Fermentation strategy for an acetoin-controlled overproduction of heterologous proteins.

Indexed as

AcetoinBacillus subtilisMicroorganisms, Genetically-ModifiedBacterial ProteinsFermentationPlasmidsPromoter Regions, GeneticAcetoinBacterial ProteinsBacillus subtilisExpression systemFed batchHuman interleukin-1βOverproductionProtease deficiencyProtein secretionYeast sulfhydryl oxidase

Identifiers

PMID35802157
PMCPMC9329435
OpenAlexW4284898250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.